UKGulf Trade Deal Hailed as Monumental Achievement by Bahrain Minister NFL Seeks Ban on Certain Sports Prediction Contracts Including GameSpecific Bets and Injury Markets Luhansk Strike Escalates Tensions Potential Economic Repercussions as Russia Vows Retaliation London Stock Exchange Group Reports Income Growth Driven by Tradeweb Platform SiTime Corporation SITM Plans 12 Billion Convertible Notes Offering to Fund Renesas Timing Business Acquisition Inflation Squeeze Travel Recreation and Food Prices Surge Ahead of Memorial Day Weekend ALMS Q1 2026 Earnings EPS Beat Partially Offsets Investor Concerns NVST Q1 2026 Earnings EPS Beats Estimates Despite Stock Decline TG Therapeutics Q1 2026 Earnings EPS Disappoints as Stock Declines Ainos Inc AIMD Q1 2025 Earnings Breakthrough Pipeline Progress Drives Massive Stock Surge Despite No Revenue Integra Resources Corp Q1 2026 Earnings EPS Miss Amid PreRevenue Development Stage WKHS Q1 2026 Earnings Deepening Losses Amid Operational Transition Park Hotels Resorts PK Rallies 3 Support Holds Resistance in Sight Tianci International Inc CIIT Holds Steady Near Support Level as Trading Activity Remains Light Caesarstone Shares Slide Over 7 Key Levels Under Pressure Micron Technology MU Slips 146 as Bullish Momentum Fades Near 750 Donegal Group Inc DGICB Holds Steady at 1829 Amid Quiet Trading BSE NSE to Remain Closed on Bakri Id Stock Market Holiday on May 28 2026 NU Q1 2026 Earnings EPS Misses Expectations Despite Positive Stock Reaction Pelthos Therapeutics Inc PTHS Declines 263 as Stock Tests Key Support Levels Castle Biosciences CSTL Faces Pullback Amid Market Volatility Key Levels in Focus Centurion Acquisition Corp ALF SPAC Holds Steady Near 1088 Amid Minimal Movement ADTRAN Holdings Inc ADTN Edges Higher as Shares Approach Key Resistance Level AMN Healthcare Services AMN Rallies 268 Approaches Resistance at 2933 STERIS STE Faces Modest Pullback as Shares Test Key Technical Zone Renasant Corporation RNST Holds Near Key Support as Modest Gains Signal Stabilization Crinetics Pharmaceuticals CRNX Slips 152 as Biotech Sentiment Remains Cautious